Having placed leaders into roles like this repeatedly, we wrote this to give a practitioner’s view rather than generic advice. Biosimilars companies need executives who can hold two things at once: the scientific and manufacturing sophistication of biologics development, and the cost discipline and launch timing instincts of a competitive generics business. Very few executives have genuinely operated in both worlds, which makes biosimilars hiring one of the harder searches in life sciences.
Key Takeaways
- Biosimilars demand biologics sophistication with generic economics.
- Analytical comparability work is scientifically demanding.
- Manufacturing capability is a primary competitive differentiator.
- Interchangeability and substitution rules shape commercial strategy.
- Candidates fluent in both models are genuinely scarce.
Two Demanding Disciplines at Once
Developing a biosimilar requires substantial analytical and manufacturing science: demonstrating comparability to a reference biologic across a range of characteristics, managing the variability inherent in biological production, and building manufacturing capability that produces consistent product at scale. Simultaneously, the commercial reality is competitive and price-driven, with returns dependent on launch timing and cost position. Executives from innovator biologics backgrounds often bring the science without the cost discipline; executives from small molecule generics bring the economics without the biologics capability. Neither alone is sufficient.
Manufacturing as Competitive Advantage
In biosimilars, manufacturing capability is not a support function but a primary competitive differentiator: the ability to produce consistently at scale and cost determines whether the economics work. This raises the importance of manufacturing and technical operations leadership relative to many other pharmaceutical contexts, and it means these roles should be filled with genuine biologics manufacturing depth rather than adapted from small molecule experience. Companies that underweight this find their cost position uncompetitive regardless of commercial execution.
Regulatory and Substitution Complexity
Biosimilar regulatory pathways involve comparability exercises rather than full clinical development, and the rules governing substitution and interchangeability vary by jurisdiction and materially affect commercial uptake. Leaders in regulatory and commercial roles need genuine understanding of how these frameworks operate in the markets that matter to the company, since strategy built on assumptions imported from small molecule generics, where substitution is often automatic, can misjudge uptake substantially. Assess this specifically rather than assuming generic regulatory experience covers it.
Finding the Rare Combination
Given how few executives have genuine dual fluency, biosimilars companies usually must build teams that combine complementary depth rather than finding individuals who hold everything. That means being explicit about which capability each senior role must own, ensuring the leadership team collectively covers biologics science, manufacturing, cost discipline, and market-specific commercial understanding, and hiring for genuine willingness to work across those boundaries. Searching for the mythical fully-fluent candidate usually wastes time that would be better spent designing a complementary team.
What This Looks Like in Practice
A biosimilars company defines explicitly which capability each senior role must own, builds a leadership team that collectively covers biologics science, manufacturing depth, cost discipline, and market-specific commercial understanding, weights biologics manufacturing experience heavily, and assesses genuine understanding of substitution and interchangeability in its target markets.
The Mistake Employers Keep Making
The most common mistake is hiring from small molecule generics on the strength of cost and launch discipline, assuming biologics is a technical detail the organisation can absorb. Analytical comparability, biological variability, and manufacturing consistency are genuinely demanding, and leadership without that depth tends to underestimate development difficulty and cost, producing timelines and budgets that do not hold.
Capabilities a Biosimilars Team Must Cover
| Capability | Typical Source |
|---|---|
| Analytical comparability science | Innovator biologics background |
| Biologics manufacturing at scale | Biologics technical operations |
| Cost discipline and launch timing | Generics background |
| Substitution and interchangeability | Market-specific regulatory and commercial |
| Portfolio and capital judgment | Either, with genuine adaptation |
The Bottom Line
Biosimilars companies need biologics scientific and manufacturing sophistication alongside generic cost and timing discipline, a combination few individuals hold, so design a leadership team that covers these complementarily rather than searching for a single fully-fluent candidate, and weight biologics manufacturing depth heavily. Get this right and the hire becomes a genuine multiplier; get it wrong and no amount of general talent compensates.
Related Reading
For more, see Hiring Executives with Both Innovator and Generics Experience, Recruiting Leadership for Generic Drug Manufacturers, Hiring Trends in Pharmaceutical Manufacturing Leadership.
Frequently Asked Questions
- Q: What makes biosimilars hiring difficult?
- A: The business requires biologics scientific and manufacturing sophistication together with generic cost discipline and launch timing instincts, and few executives have operated genuinely in both worlds.
- Q: Why is manufacturing so central?
- A: Because the ability to produce consistently at scale and cost is a primary competitive differentiator in biosimilars, determining whether the economics work at all.
- Q: How do biosimilar regulatory pathways differ?
- A: They centre on comparability exercises rather than full clinical development, with substitution and interchangeability rules varying by jurisdiction and materially affecting uptake.
- Q: Can small molecule generics leaders run biosimilars?
- A: Only with genuine biologics depth alongside them, since analytical comparability, biological variability, and manufacturing consistency are demanding and easily underestimated.
- Q: What is the practical hiring approach?
- A: Design a leadership team covering biologics science, manufacturing, cost discipline, and market-specific commercial understanding complementarily rather than seeking one fully-fluent individual.
![](https://www.jrgpartners.com/wp-content/uploads/2025/12/tanya-gallardo.jpeg")
Tanya Gallardo
Managing Director, Executive Search & AI Talent Strategy
Tanya Gallardo is the Managing Director of Executive Search & AI Talent Strategy at JRG Partners, leading C-suite and Board engagements across key growth sectors including Technology, Financial Services, and Manufacturing.
With over 18 years of experience specializing in disruptive technology leadership, Tanya is recognized as a leading authority on talent architecture for future-focused executive roles, such as the Chief AI Officer (CAIO) and Chief Digital Officer (CDO). Her expertise lies in accurately assessing the cultural fit and technical depth required to ensure a high return on investment (ROI) for critical leadership appointments.
Prior to her role at JRG Partners, Tanya held senior roles directing global talent acquisition strategies at a major publicly-traded technology firm, advising on organizational design and succession planning for emerging executive functions. She is a recognized speaker and contributor to industry events, sharing data-driven insights on executive compensation, leadership development, and the measurable business impact of C-suite talent.
